EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieOpen Access

Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation

Stephen J Nicholls, Steven E Nissen, Cynthia Fleming, Shweta Urva, Jeffrey Suico, Paul H Berg, Helle Linnebjerg, Giacomo Ruotolo, P Kellie Turner, Laura F Michael

JAMA · 19.09.2023 · 330 (11) · 1042

DOI: 10.1001/jama.2023.16503 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift JAMA, erschienen am 19.09.2023. Verfasst von Stephen J Nicholls und 9 weiteren Autor:innen. Beteiligte Einrichtung: Victorian Heart Institute, Monash University, Clayton, Victoria, Australia. Hauptthemen laut MEDLINE: Lipoprotein(a), Cardiovascular Agents, Hypolipidemic Agents. Die Arbeit wurde bisher 214-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Lipoprotein(a) (Lp[a]) is associated with atherosclerotic disease and aortic stenosis. Lp(a) forms by bonding between apolipoprotein(a) (apo[a]) and apo B 100 . Muvalaplin is an orally administered small molecule that inhibits Lp(a) formation by blocking the apo(a)-apo B 100 interaction while avoiding interaction with a homologous protein, plasminogen.

Objective

To determine the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of muvalaplin. Design, Setting, and Participants This phase 1 randomized, double-blind, parallel-design study enrolled 114 participants (55 assigned to a single-ascending dose; 59 assigned to a multiple-ascending dose group) at 1 site in the Netherlands.

Interventions

The single ascending dose treatment evaluated the effect of a single dose of muvalaplin ranging from 1 mg to 800 mg or placebo taken by healthy participants with any Lp(a) level. The multiple ascending dose treatment evaluated the effect of taking daily doses of muvalaplin (30 mg to 800 mg) or placebo for 14 days in patients with Lp(a) levels of 30 mg/dL or higher. Main Outcomes and Measures Outcomes included safety, tolerability, pharmacokinetics, and exploratory pharmacodynamic biomarkers.

Results

Among 114 randomized (55 in the single ascending dose group: mean [SD] age, 29 [10] years, 35 females [64%], 2 American Indian or Alaska Native [4%], 50 White [91%], 3 multiracial [5%]; 59 in the multiple ascending dose group: mean [SD] age 32 [15] years; 34 females [58%]; 3 American Indian or Alaska Native [5%], 6 Black [10%], 47 White [80%], 3 multiracial [5%]), 105 completed the trial. Muvalaplin was not associated with tolerability concerns or clinically significant adverse effects. Oral doses of 30 mg to 800 mg for 14 days resulted in increasing muvalaplin plasma concentrations and half-life ranging from 70 to 414 hours. Muvalaplin lowered Lp(a) plasma levels within 24 hours after the first dose, with further Lp(a) reduction on repeated dosing. Maximum placebo-adjusted Lp(a) reduction was 63% to 65%, resulting in Lp(a) plasma levels less than 50 mg/dL in 93% of participants, with similar effects at daily doses of 100 mg or more. No clinically significant changes in plasminogen levels or activity were observed.

Conclusion

Muvalaplin, a selective small molecule inhibitor of Lp(a) formation, was not associated with tolerability concerns and lowered Lp(a) levels up to 65% following daily administration for 14 days. Longer and larger trials will be required to further evaluate safety, tolerability, and effect of muvalaplin on Lp(a) levels and cardiovascular outcomes. Trial Registration ClinicalTrials.gov Identifier: NCT04472676

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lipoprotein(a)Cardiovascular AgentsHypolipidemic AgentsAdultFemaleHumansAmerican Indian or Alaska NativeApoprotein(a)Administration, OralDouble-Blind MethodMaleAdolescentYoung AdultMiddle AgedDose-Response Relationship, DrugWhiteBlack or African AmericanRacial Groups

Substanzen

Apoprotein(a)Lipoprotein(a)Cardiovascular AgentsHypolipidemic Agents

Autor:innen und Institutionen

  • Victorian Heart Institute, Monash University, Clayton, Victoria, Australia.
  • Cleveland Clinic Coordinating Center for Clinical Research, Cleveland Clinic, Cleveland, Ohio.
  • Eli Lilly and Company, Indianapolis, Indiana.

Zitieren

APA

Nicholls, S. J., Nissen, S. E., Fleming, C., Urva, S., Suico, J., Berg, P. H., Linnebjerg, H., Ruotolo, G., Turner, P. K., & Michael, L. F. (2023). Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation. JAMA, 330(11), 1042. https://doi.org/10.1001/jama.2023.16503

Vancouver

Nicholls SJ, Nissen SE, Fleming C, Urva S, Suico J, Berg PH, et al. Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation. JAMA. 2023;330(11):1042. doi:10.1001/jama.2023.16503

BibTeX
@article{Nicholls2023,
  author = {Nicholls, Stephen J and Nissen, Steven E and Fleming, Cynthia and Urva, Shweta and Suico, Jeffrey and Berg, Paul H and Linnebjerg, Helle and Ruotolo, Giacomo and Turner, P Kellie and Michael, Laura F},
  title = {Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation},
  journal = {JAMA},
  year = {2023},
  volume = {330},
  number = {11},
  pages = {1042},
  doi = {10.1001/jama.2023.16503}
}
Kostenlos starten →